KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Common Equity: 2018-2024

Historic Common Equity for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Dec 2024 value amounting to $377.5 million.

  • Aurinia Pharmaceuticals' Common Equity fell 5.73% to $365.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $365.8 million, marking a year-over-year decrease of 5.73%. This contributed to the annual value of $377.5 million for FY2024, which is 0.13% down from last year.
  • Aurinia Pharmaceuticals' Common Equity amounted to $377.5 million in FY2024, which was down 0.13% from $378.0 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Common Equity registered a high of $479.1 million during FY2021, and its lowest value of $377.5 million during FY2024.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Common Equity value was $378.0 million (recorded in 2023), while the average stood at $387.0 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Common Equity surged by 36.55% in 2020, and later dropped by 15.37% in 2022.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Common Equity stood at $407.8 million in 2020, then rose by 17.50% to $479.1 million in 2021, then declined by 15.37% to $405.4 million in 2022, then dropped by 6.78% to $378.0 million in 2023, then dropped by 0.13% to $377.5 million in 2024.